Zoetis (ZTS) Remains a Leader, So Why Was It Sold?

20 hours ago 4

Attiya Zainib

Fri, August 14, 2026 astatine 9:26 AM CDT 3 min read

Polen Capital Management Llc released its "Polen Focus Growth Strategy" Q2 2026 capitalist letter. A transcript of the missive tin beryllium downloaded here. Polen Focus Growth returned 6.33% (net of fees) successful the 2nd 4th of 2026, importantly underperforming the Russell 1000 Growth Index's 16.74% gain, arsenic the marketplace rally remained narrowly focused connected AI infrastructure and semiconductor stocks. During the quarter, Polen Capital repositioned the portfolio toward companies benefiting from structural maturation successful AI infrastructure, powerfulness demand, and aerospace. Looking ahead, the managers stay assured successful the semipermanent net imaginable of the portfolio but admit that changing marketplace dynamics and the rising accidental outgo of patience necessitate a much nimble approach. They stay focused connected competitively advantaged businesses with durable maturation prospects, portion selectively participating successful AI infrastructure, commercialized aerospace, and powerfulness infrastructure opportunities wherever proviso constraints and semipermanent request could enactment sustained net growth. In addition, delight cheque the Fund's apical 5 holdings to cognize its champion picks successful 2026.

In its second-quarter 2026 capitalist letter, Polen Focus Growth Strategy highlighted stocks similar Zoetis Inc. (NYSE:ZTS). Zoetis Inc. (NYSE:ZTS) is simply a planetary carnal wellness institution that develops medicines, vaccines, and diagnostic products for livestock and companion animals. The one-month instrumentality of Zoetis Inc. (NYSE:ZTS) was -0.94% portion its shares traded betwixt $71.45 and $160.48 over the past 52 weeks. On August 13, 2026, Zoetis Inc. (NYSE:ZTS) banal closed astatine astir $73.54 per share, with a marketplace capitalization of astir $31.34 billion.

Polen Focus Growth Strategy stated the pursuing regarding Zoetis Inc. (NYSE:ZTS) in its Q2 2026 capitalist letter:

We sold Zoetis Inc. (NYSE:ZTS). Zoetis remains the planetary person successful carnal health and retains galore of the characteristics we admire: beardown brands, scale, recurring demand, and a agelong runway for innovation. However, the concern has slowed owed successful portion to competitory entry in dermatology, an important maturation country for the company. We expect Zoetis to instrumentality to amended maturation implicit time, supported by a pipeline of caller merchandise launches, but we deliberation that acceleration is improbable to reconstruct gross maturation to high-single-digit levels until precocious adjacent year. We volition proceed to travel the institution closely and would see reinvesting if the acceleration becomes more visible. For now, we judge the superior is amended deployed into businesses that we deliberation person stronger existent momentum, including ATI, GE Aerospace, and GE Vernova.

Read Entire Article